TCR-话题@MedSci

#TCR#

24篇内容 | 1078人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1518953, encodeId=3fa1151895383, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=肿瘤免疫中TCR-T细胞治疗的研究进展, objectType=article, longId=734444, objectId=7e2ee34444b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e2ee34444b0, replyNumber=0, likeNumber=52, createdTime=2022-08-06, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e2ee34444b0, moduleTitle=肿瘤免疫中TCR-T细胞治疗的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e2ee34444b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518952, encodeId=59db15189520d, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., objectType=article, longId=218899, objectId=169221889999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=169221889999, replyNumber=0, likeNumber=33, createdTime=2021-10-21, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=169221889999, moduleTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=169221889999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518951, encodeId=7ab81518951a0, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=NICE将新型抗生素Fetcroja（cefiderocol）纳入试点报销范围, objectType=article, longId=205044, objectId=c2e52050447d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2e52050447d, replyNumber=0, likeNumber=34, createdTime=2021-01-01, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2e52050447d, moduleTitle=NICE将新型抗生素Fetcroja（cefiderocol）纳入试点报销范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2e52050447d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518950, encodeId=3c221518950d0, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=李懿点评 | TCR-T细胞疗法，三大障碍有待突破, objectType=article, longId=200496, objectId=598f20049681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=598f20049681, replyNumber=0, likeNumber=38, createdTime=2020-09-11, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=598f20049681, moduleTitle=李懿点评 | TCR-T细胞疗法，三大障碍有待突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=598f20049681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518949, encodeId=ab4d151894999, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=Blood：CD19-CAR-T细胞的内源性TCR表达的去留？, objectType=article, longId=195465, objectId=d8e3195465aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8e3195465aa, replyNumber=0, likeNumber=49, createdTime=2020-06-09, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8e3195465aa, moduleTitle=Blood：CD19-CAR-T细胞的内源性TCR表达的去留？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8e3195465aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518948, encodeId=f65b151894809, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=欧盟批准Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重点革兰氏阴性病原体, objectType=article, longId=193318, objectId=de90193318ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de90193318ff, replyNumber=0, likeNumber=41, createdTime=2020-05-03, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de90193318ff, moduleTitle=欧盟批准Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重点革兰氏阴性病原体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de90193318ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518947, encodeId=ed62151894e89, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=欧洲药品管理局CHMP推荐了抗耐药菌药物Fetcroja和抗感染药物Tigecycline上市, objectType=article, longId=189500, objectId=7a3e18950020, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a3e18950020, replyNumber=0, likeNumber=34, createdTime=2020-03-08, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a3e18950020, moduleTitle=欧洲药品管理局CHMP推荐了抗耐药菌药物Fetcroja和抗感染药物Tigecycline上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a3e18950020)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518946, encodeId=25d715189464f, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线, objectType=article, longId=186503, objectId=f6d21865035f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6d21865035f, replyNumber=0, likeNumber=26, createdTime=2020-01-20, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6d21865035f, moduleTitle=新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6d21865035f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518945, encodeId=d57d151894516, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=Blood：耗竭TCRαβ+/CD19+细胞可有效预防移植物抗宿主病(GVHD)，同时降低对供体匹配度的要求, objectType=article, longId=180391, objectId=f6531803912c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6531803912c, replyNumber=0, likeNumber=29, createdTime=2019-10-04, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6531803912c, moduleTitle=Blood：耗竭TCRαβ+/CD19+细胞可有效预防移植物抗宿主病(GVHD)，同时降低对供体匹配度的要求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6531803912c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518944, encodeId=094b151894493, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器, objectType=article, longId=177005, objectId=aca81e700547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aca81e700547, replyNumber=0, likeNumber=31, createdTime=2019-08-08, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aca81e700547, moduleTitle=TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aca81e700547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518943, encodeId=538815189433a, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=完全个体化肿瘤免疫疗法：一种针对个体化抗原的自体基因编辑的TCR T细胞疗法（NeoTCR-P1）, objectType=article, longId=175924, objectId=f0c91e5924d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0c91e5924d3, replyNumber=0, likeNumber=40, createdTime=2019-07-23, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0c91e5924d3, moduleTitle=完全个体化肿瘤免疫疗法：一种针对个体化抗原的自体基因编辑的TCR T细胞疗法（NeoTCR-P1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0c91e5924d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518942, encodeId=1950151894278, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=重磅！2017（第三届）下一代CAR&TCR-T研讨会即将召开, objectType=article, longId=114813, objectId=af551148136e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af551148136e, replyNumber=0, likeNumber=0, createdTime=2017-10-01, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af551148136e, moduleTitle=重磅！2017（第三届）下一代CAR&TCR-T研讨会即将召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af551148136e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518941, encodeId=965d15189419f, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=盖茨基金会投资4000万美元支持TCR-T疗法, objectType=article, longId=113522, objectId=2b0111352213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0111352213, replyNumber=0, likeNumber=36, createdTime=2017-09-22, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0111352213, moduleTitle=盖茨基金会投资4000万美元支持TCR-T疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0111352213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518940, encodeId=57c2151894018, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=新加坡政府大力支持Lion TCR生物公司产品的国际商业化, objectType=article, longId=111385, objectId=6cb611138583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cb611138583, replyNumber=0, likeNumber=44, createdTime=2017-09-01, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cb611138583, moduleTitle=新加坡政府大力支持Lion TCR生物公司产品的国际商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cb611138583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518939, encodeId=f26d15189391b, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=美国FDA授予Lion TCR两项针对肝癌T细胞疗法的孤儿药物资格, objectType=article, longId=110518, objectId=cc0311051889, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc0311051889, replyNumber=0, likeNumber=28, createdTime=2017-08-24, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc0311051889, moduleTitle=美国FDA授予Lion TCR两项针对肝癌T细胞疗法的孤儿药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0311051889)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518938, encodeId=27021518938ea, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=继CAR-T之后，TCR技术或成为第3代免疫疗法明星, objectType=article, longId=105401, objectId=481810540199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=481810540199, replyNumber=0, likeNumber=33, createdTime=2017-07-14, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=481810540199, moduleTitle=继CAR-T之后，TCR技术或成为第3代免疫疗法明星, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=481810540199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518937, encodeId=de86151893e77, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=SCI REP：舌癌和肺癌中,由c-Myc转录调节的TCRP1赋予了癌症药物抗性, objectType=article, longId=102477, objectId=89061024e70b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89061024e70b, replyNumber=0, likeNumber=37, createdTime=2017-06-21, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89061024e70b, moduleTitle=SCI REP：舌癌和肺癌中,由c-Myc转录调节的TCRP1赋予了癌症药物抗性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89061024e70b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518936, encodeId=d766151893684, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=Cell Res：TCR激活过程中CD3依赖磷脂膜的动态变化机制, objectType=article, longId=95359, objectId=3d4b95359c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4b95359c6, replyNumber=0, likeNumber=37, createdTime=2017-04-12, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4b95359c6, moduleTitle=Cell Res：TCR激活过程中CD3依赖磷脂膜的动态变化机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d4b95359c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518935, encodeId=f7bc1518935f1, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=综述：CAR-T疗法、TCR-T疗法研发格局, objectType=article, longId=87275, objectId=13948e275d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13948e275d4, replyNumber=0, likeNumber=38, createdTime=2017-01-13, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13948e275d4, moduleTitle=综述：CAR-T疗法、TCR-T疗法研发格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13948e275d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1518934, encodeId=80fd1518934bf, content=<a href='/topic/show?id=c8bb1e20902' target=_blank style='color:#2F92EE;'>#TCR#</a>, objectTitle=2016 下一代CAR&TCR-T研讨会, objectType=article, longId=73173, objectId=2558e3173ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2558e3173ec, replyNumber=0, likeNumber=21, createdTime=2016-09-22, rootId=0, userName=Boyinsh, userId=a6b511213226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2558e3173ec, moduleTitle=2016 下一代CAR&TCR-T研讨会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2558e3173ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TCR

2020-05-29

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

肿瘤免疫中TCR-T细胞治疗的研究进展

2022-08-06

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc.

2021-10-21

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

NICE将新型抗生素Fetcroja（cefiderocol）纳入试点报销范围

2021-01-01

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

李懿点评 | TCR-T细胞疗法，三大障碍有待突破

2020-09-11

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

Blood：CD19-CAR-T细胞的内源性TCR表达的去留？

2020-06-09

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

欧盟批准Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重点革兰氏阴性病原体

2020-05-03

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

欧洲药品管理局CHMP推荐了抗耐药菌药物Fetcroja和抗感染药物Tigecycline上市

2020-03-08

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线

2020-01-20

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

Blood：耗竭TCRαβ+/CD19+细胞可有效预防移植物抗宿主病(GVHD)，同时降低对供体匹配度的要求

2019-10-04

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器

2019-08-08

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

完全个体化肿瘤免疫疗法：一种针对个体化抗原的自体基因编辑的TCR T细胞疗法（NeoTCR-P1）

2019-07-23

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

重磅！2017（第三届）下一代CAR&TCR-T研讨会即将召开

2017-10-01

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

盖茨基金会投资4000万美元支持TCR-T疗法

2017-09-22

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

新加坡政府大力支持Lion TCR生物公司产品的国际商业化

2017-09-01

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

美国FDA授予Lion TCR两项针对肝癌T细胞疗法的孤儿药物资格

2017-08-24

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

继CAR-T之后，TCR技术或成为第3代免疫疗法明星

2017-07-14

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

SCI REP：舌癌和肺癌中,由c-Myc转录调节的TCRP1赋予了癌症药物抗性

2017-06-21

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

Cell Res：TCR激活过程中CD3依赖磷脂膜的动态变化机制

2017-04-12

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

综述：CAR-T疗法、TCR-T疗法研发格局

2017-01-13

Boyinsh (审核中...)

前往app查看评论内容

#TCR#

2016 下一代CAR&TCR-T研讨会

2016-09-22

科室
- - 订阅+
  - 更多科室
工具
服务